This study is looking at ways to improve how quickly children with status epilepticus (SE), which is a long-lasting seizure, receive treatment. Researchers are testing a "quality improvement bundle" that includes using intranasal or buccal midazolam (a type of benzodiazepine, or BZD, medication) as the first treatment, aiming to give this medicine within 10 minutes of the seizure starting, and making sure all necessary supplies are readily available. The study wants to see if these changes can reduce the time it takes to give the first dose of BZD after SE is diagnosed in hospitalized children who are not critically ill. This could help lower the risk of complications and death. Children aged 30 days to 18 years who experience a continuous seizure lasting over 5 minutes, or any continuous seizure for which they receive a BZD, may be able to participate. The current recruitment status is unclear.

Study design

This study is a stepped-wedge cluster randomized trial involving 450 participants across seven centers. All centers will eventually implement the same quality improvement bundle, but at different times.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 30 days, suggesting participants will be followed for at least this long after diagnosis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.